SCHEMBL18979428

SCHEMBL18979428

Cc1ncc(C(=O)Nc2ccc(-c3cc(NC4CC4)cc(N4CCN(C)CC4)c3)c(C)n2)cn1

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 6/20 0.41
LDLR P01130 1/20 0.41
PCSK9 Q8NBP7 1/20 0.41
GSK3B P49841 3/20 0.41
FLT3 P36888 3/20 0.40
KDR P35968 1/20 0.40
F10 P00742 6/20 0.39
WNT1 P04628 3/20 0.39
BRD4 O60885 1/20 0.38
SYK P43405 1/20 0.38
ABL1 P00519 1/20 0.38
PRKCI P41743 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17027858 0.87 DYRK1A (0.47) DYRK1ALDLRPCSK9GSK3BFLT3
SCHEMBL17027809 0.86 DYRK1A (0.42) DYRK1AGSK3BF10WNT1ABL1
SCHEMBL17027749 0.86 F10 (0.48) DYRK1AGSK3BF10WNT1
SCHEMBL18979453 0.83 PIK3CA (0.46) DYRK1AFLT3KDRF10
SCHEMBL28754069 0.83 F10 (0.44) DYRK1AGSK3BF10WNT1
SCHEMBL23635155 0.76 LDLR (0.38) DYRK1ALDLRPCSK9GSK3BFLT3
SCHEMBL18996612 0.73 DYRK1A (0.48) DYRK1AGSK3BF10WNT1ABL1
SCHEMBL28941910 0.72 DYRK1A (0.49) DYRK1AGSK3BF10WNT1
SCHEMBL17027818 0.72 F10 (0.54) DYRK1AGSK3BF10WNT1
SCHEMBL18979456 0.71 F10 (0.61) DYRK1AGSK3BFLT3F10WNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034101-A1 ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS FROST BIOLOGIC INC (US) 2026-02-05 US disclosed
US-12383533-B2 Antimitotic amides for the treatment of cancer and proliferative disorders FROST BIOLOGIC, INC. (US) 2025-08-12 US disclosed
CN-114634483-B Antimitotic amides for the treatment of cancer and proliferative diseases 弗洛斯特生物科技有限公司 2024-08-13 CN disclosed
CN-114634483-A Antimitotic amides for the treatment of cancer and proliferative diseases 弗洛斯特生物科技有限公司 2022-06-17 CN disclosed
US-20220008395-A1 ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS FROST BIOLOGIC, INC. 2022-01-13 US disclosed
US-20220008395-A1 ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS FROST BIOLOGIC, INC. 2022-01-13 US disclosed
US-11129813-B2 Antimitotic amides for the treatment of cancer and proliferative disorders FROST BIOLOGIC, INC. (US) 2021-09-28 US disclosed
US-11129813-B2 Antimitotic amides for the treatment of cancer and proliferative disorders FROST BIOLOGIC, INC. (US) 2021-09-28 US disclosed
EP-3107909-B1 ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS FROST BIOLOGIC INC (US) 2021-07-14 EP disclosed
EP-3107909-B1 ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS FROST BIOLOGIC INC (US) 2021-07-14 EP disclosed
US-20200397758-A1 Antimitotic Amides for the Treatment of Cancer and Proliferative Disorders FROST BIOLOGIC, INC. 2020-12-24 US disclosed
US-10772872-B2 Antimitotic amides for the treatment of cancer and proliferative disorders FROST BIOLOGIC, INC. (US) 2020-09-15 US disclosed
US-10772872-B2 Antimitotic amides for the treatment of cancer and proliferative disorders FROST BIOLOGIC, INC. (US) 2020-09-15 US disclosed
US-20180325871-A1 ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS FROST BIOLOGIC, INC. (US) 2018-11-15 US disclosed
US-10016398-B2 Antimitotic amides for the treatment of cancer and proliferative disorders FROST BIOLOGIC, INC. (US) 2018-07-10 US disclosed
US-10016398-B2 Antimitotic amides for the treatment of cancer and proliferative disorders FROST BIOLOGIC, INC. (US) 2018-07-10 US disclosed
US-10016398-B2 Antimitotic amides for the treatment of cancer and proliferative disorders FROST BIOLOGIC, INC. (US) 2018-07-10 US disclosed
US-20170172984-A1 ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS FROST BIOLOGIC, INC. (US) 2017-06-22 US disclosed
US-20170172984-A1 ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS FROST BIOLOGIC, INC. (US) 2017-06-22 US disclosed
US-20170172984-A1 ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS FROST BIOLOGIC, INC. (US) 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220008395-A1 ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS CCNA1, CCNE1, CCNB1 DYRK1A 1713/4885LDLR 3825/4885PCSK9 3941/4885
US-20260034101-A1 ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS NCOR1, NR0B1, NCOR2 DYRK1A 1592/4885LDLR 406/4885PCSK9 4605/4885
US-20180325871-A1 ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS CCNA1, CCNE1, CCNB1 DYRK1A 1713/4885LDLR 3825/4885PCSK9 3941/4885
US-12383533-B2 Antimitotic amides for the treatment of cancer and proliferative disorders CCNA1, CCNE1, CCNB1 DYRK1A 1713/4885LDLR 3825/4885PCSK9 3941/4885
US-10016398-B2 Antimitotic amides for the treatment of cancer and proliferative disorders CCNA1, CCNE1, CCNB1 DYRK1A 1713/4885LDLR 3825/4885PCSK9 3941/4885
US-11129813-B2 Antimitotic amides for the treatment of cancer and proliferative disorders CCNA1, CCNE1, CCNB1 DYRK1A 1713/4885LDLR 3825/4885PCSK9 3941/4885
US-10772872-B2 Antimitotic amides for the treatment of cancer and proliferative disorders CCNA1, CCNE1, CCNB1 DYRK1A 1713/4885LDLR 3825/4885PCSK9 3941/4885
US-20200397758-A1 Antimitotic Amides for the Treatment of Cancer and Proliferative Disorders CCNA1, CCNE1, CCNB1 DYRK1A 1713/4885LDLR 3825/4885PCSK9 3941/4885
US-20170172984-A1 ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS CCNA1, CCNE1, CCNB1 DYRK1A 1713/4885LDLR 3825/4885PCSK9 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.